WO2005003288A3 - Diagnostic methods , prognostic methods and pharmaceutical compositions for neurodegenerative diseases like alzheimer’s disease by modulating and investigating genes rgs4 and itpkb, their gene products or fragments and derivatives thereof - Google Patents

Diagnostic methods , prognostic methods and pharmaceutical compositions for neurodegenerative diseases like alzheimer’s disease by modulating and investigating genes rgs4 and itpkb, their gene products or fragments and derivatives thereof Download PDF

Info

Publication number
WO2005003288A3
WO2005003288A3 PCT/SE2004/001079 SE2004001079W WO2005003288A3 WO 2005003288 A3 WO2005003288 A3 WO 2005003288A3 SE 2004001079 W SE2004001079 W SE 2004001079W WO 2005003288 A3 WO2005003288 A3 WO 2005003288A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
itpkb
rgs4
disease
alzheimer
Prior art date
Application number
PCT/SE2004/001079
Other languages
French (fr)
Other versions
WO2005003288A2 (en
Inventor
Elena Jazin
Lina Emilsson
Original Assignee
Elena Jazin
Lina Emilsson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elena Jazin, Lina Emilsson filed Critical Elena Jazin
Publication of WO2005003288A2 publication Critical patent/WO2005003288A2/en
Publication of WO2005003288A3 publication Critical patent/WO2005003288A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to diagnostic and prognostic methods for Alzheimer's Disease. The methods comprise measuring altered expression levels of the genes RGS4 and ITPKB in samples from a subject. The inventions also relate to kits for performing the method, and methods for screening for agents modulating expression of RGS4 and/or ITPKB, as well as the use of such agents for treating Alzheimer's Disease and manufacturing pharmaceutical compositions.
PCT/SE2004/001079 2003-07-02 2004-07-02 Diagnostic methods , prognostic methods and pharmaceutical compositions for neurodegenerative diseases like alzheimer’s disease by modulating and investigating genes rgs4 and itpkb, their gene products or fragments and derivatives thereof WO2005003288A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48431703P 2003-07-02 2003-07-02
US60/484,317 2003-07-02

Publications (2)

Publication Number Publication Date
WO2005003288A2 WO2005003288A2 (en) 2005-01-13
WO2005003288A3 true WO2005003288A3 (en) 2005-03-10

Family

ID=33563977

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE2004/001079 WO2005003288A2 (en) 2003-07-02 2004-07-02 Diagnostic methods , prognostic methods and pharmaceutical compositions for neurodegenerative diseases like alzheimer’s disease by modulating and investigating genes rgs4 and itpkb, their gene products or fragments and derivatives thereof

Country Status (1)

Country Link
WO (1) WO2005003288A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007140975A1 (en) * 2006-06-06 2007-12-13 F. Hoffmann-La Roche Ag Synaptic proteins as biomarker for alzheimer’s disease
WO2013049026A2 (en) * 2011-09-29 2013-04-04 The Uab Research Foundation Neurabin scaffolding of the adenosine receptor and rgs4 regulates anti-seizure effect of endogenous adenosine
CN117051096A (en) * 2017-12-08 2023-11-14 神经Gx有限责任公司 Synchronized cell cycle gene expression assays for Alzheimer's disease and related therapeutic methods
CN113801929A (en) * 2020-06-11 2021-12-17 香港科技大学 Method for identifying a drug capable of treating alzheimer's disease

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040053821A1 (en) * 2002-02-15 2004-03-18 The Regents Of The University Of Michigan Inhibitors of RGS proteins

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040053821A1 (en) * 2002-02-15 2004-03-18 The Regents Of The University Of Michigan Inhibitors of RGS proteins

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GEURTS M. ET AL.: "Altered expression of regulators of G-protein signaling (RGS) mRNAs in the striatum of rats undergoing dopamine depletion", BIOCHEMICAL PHARMACOLOGY, vol. 66, 2003, pages 1163 - 1170 *
MUMA N.A. ET AL.: "Differences in regional and subcellular localization of G9/11 and RGS4 protein levels in Alzheimer's disease: correlation with muscarinic M1 receptor binding parameters", SYNAPSE, vol. 47, 2003, pages 58 - 65 *
ZHONG H. ET AL.: "Regulator of G protein signaling proteins: novel multifunctional drug targets", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 297, no. 3, 2001, pages 837 - 845 *

Also Published As

Publication number Publication date
WO2005003288A2 (en) 2005-01-13

Similar Documents

Publication Publication Date Title
ATE350486T1 (en) GENES INDUCED BY MECHANICAL STRESS, THEIR EXPRESSION PRODUCTS AND THEIR USE.
WO2002085285A3 (en) Methods and reagents for regulating bone and cartilage formation
WO2005098433A3 (en) Diagnostic assays for alzheimer’s disease
ATE534650T1 (en) NEW CYANOTHIAZOLIDES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICINAL PRODUCTS
DE60224383D1 (en) PROCEDURE FOR DETECTION IN YEAST TO INFLUENCE PROTEIN FOLDING
DE954602T1 (en) INHERITABLE HEMOCHROMATOSIS GENE
WO2008030273A3 (en) Compositions and methods for diagnosis and treatment of type 2 diabetes
WO2006055524A3 (en) Biomarkers for diagnosing schizophrenia and bipolar disorder
WO2006096737A3 (en) Diagnostic and therapeutic target for macular degeneration
WO2004014222A3 (en) Diagnosis and treatment of tuberous sclerosis
AU1618000A (en) Use of radioligands to screen inhibitors of amyloid-beta peptide production
KR102010859B1 (en) Markers for identifying floury endosperm characteristics and use thereof
AU2003259222A1 (en) Method of diagnosing alzheimer's disease
WO2006019685A3 (en) Compounds and their preparation for the treatment of alzheimer's disease by inhibiting beta-amyloid peptide production
WO2005003288A3 (en) Diagnostic methods , prognostic methods and pharmaceutical compositions for neurodegenerative diseases like alzheimer’s disease by modulating and investigating genes rgs4 and itpkb, their gene products or fragments and derivatives thereof
WO1999051186A3 (en) Methods and compositions for the diagnosis and treatment of neuropsychiatric disorders
WO2001020026A3 (en) POLYMORPHISMS IN THE HUMAN hPXR GENE AND THEIR USE IN DIAGNOSTIC AND THERAPEUTIC APPLICATIONS
DE03779067T1 (en) FLUORESCENCE PROTEINS AND CHROMOPROTEINS FROM NON-AEQUOREA HYDROZOA SPECIES AND METHOD FOR USE THEREOF
WO2002046767A3 (en) Diagnosis and treatment of alzheimer's disease
WO2005059105A3 (en) Cdk5 genetic markers associated with galantamine response
DE602004026683D1 (en) METHOD FOR DIAGNOSIS AND MONITORING OF NEUROLOGICAL ILLNESSES BY DETECTION OF ENCEPHALOTOXIN
WO2003054167A3 (en) Identification of novel polymorphic sites in the human mglur8 gene and uses thereof
MXPA05008394A (en) Use of the sgk gene family for diagnosis and therapy of cataracts and glaucoma.
Dienemann et al. Mutants of metal binding site M1 in APP E2 show metal specific differences in binding of heparin but not of sorLA
WO2005042706A3 (en) Ephx2 genetic markers associated with galantamine response

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase